Rhumbline Advisers Acquires 5,383 Shares of Dyne Therapeutics, Inc. $DYN

Rhumbline Advisers lifted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 4.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 133,627 shares of the company’s stock after buying an additional 5,383 shares during the period. Rhumbline Advisers owned approximately 0.12% of Dyne Therapeutics worth $1,398,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Optimize Financial Inc bought a new stake in shares of Dyne Therapeutics during the 1st quarter valued at $154,000. Exome Asset Management LLC acquired a new position in Dyne Therapeutics in the first quarter valued at about $2,703,000. Caxton Associates LLP acquired a new position in Dyne Therapeutics in the first quarter valued at about $157,000. Voleon Capital Management LP bought a new stake in Dyne Therapeutics during the first quarter worth about $624,000. Finally, Goldman Sachs Group Inc. grew its stake in Dyne Therapeutics by 58.2% during the first quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock worth $10,407,000 after buying an additional 366,183 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox bought 100,000 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, July 14th. The shares were acquired at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the acquisition, the chief executive officer directly owned 242,179 shares of the company’s stock, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 14.14% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Price Performance

DYN stock opened at $13.13 on Friday. The company has a market capitalization of $1.87 billion, a P/E ratio of -3.40 and a beta of 1.10. The company has a fifty day moving average price of $11.67 and a 200-day moving average price of $11.15. The company has a debt-to-equity ratio of 0.17, a quick ratio of 16.83 and a current ratio of 16.83. Dyne Therapeutics, Inc. has a 52-week low of $6.36 and a 52-week high of $37.04.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.02. As a group, equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of recent analyst reports. Jones Trading started coverage on shares of Dyne Therapeutics in a report on Thursday, June 26th. They set a “buy” rating and a $30.00 price target for the company. Guggenheim restated a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Chardan Capital decreased their price target on Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating on the stock in a research note on Tuesday, July 29th. Stifel Nicolaus dropped their price objective on Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, July 31st. Finally, Evercore ISI restated an “outperform” rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $34.07.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.